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WIPI2Leucine Rich Repeat Kinase 2 (LRRK2) is one of the most important genetic contributors to Parkinson's disease.
LRRK2 has been implicated in a number of cellular processes, includingmacroautophagy. To test whether LRRK2
has a role in regulating autophagy, a speciﬁc inhibitor of the kinase activity of LRRK2 was applied to human
neuroglioma cells and downstream readouts of autophagy examined. The resulting data demonstrate that inhi-
bition of LRRK2 kinase activity stimulates macroautophagy in the absence of any alteration in the translational
targets of mTORC1, suggesting that LRRK2 regulates autophagic vesicle formation independent of canonical
mTORC1 signaling. This study represents the ﬁrst pharmacological dissection of the role LRRK2 plays in the
autophagy/lysosomal pathway, emphasizing the importance of this pathway as amarker for LRRK2 physiological
function. Moreover it highlights the need to dissect autophagy and lysosomal activities in the context of LRRK2
related pathologieswith the ﬁnal aim of understanding their aetiology and identifying speciﬁc targets for disease
modifying therapies in patients.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Leucine Rich Repeat Kinase 2 (LRRK2) is a multidomain protein of
unknown function containing two enzymatic domains, a GTPase (Ras
of Complex Proteins, ROC) and a kinase, and several protein/protein in-
teraction domains [1]. LRRK2 has been implicated in a number of cellu-
lar processes, including the control of neurite branching, synaptic
vesicle recycling, macroautophagy (hereafter referred to as autophagy),
protein synthesis through the mammalian target of rapamycin (mTOR)
pathway andmitochondrial homeostasis [2]. The physiological function
of LRRK2 in the regulation of these processes is, however, unclear.
The central role of this protein in Parkinson's disease (PD) has been
highlighted by the discovery of autosomal dominant mutations in; mTOR, Mammalian target of
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lished by Elsevier B.V. All rights reserLRRK2 causing familial Parkinson's disease and the subsequent identiﬁ-
cation of the LRRK2 locus as a risk factor for sporadic disease [3,4]. A key
question regarding the role of autosomal dominant coding change
mutations in PD is what the cellular consequences of these mutations
are, and how they lead to disease [2]. Penetrant coding mutations are
found exclusively in the enzymatic core of LRRK2— theROC/COR/kinase
triptych [4], leading to a number of studies examining the impact of
mutations on the enzymatic activities of this protein. The G2019Smuta-
tion, the most common disease linked variant in LRRK2, has been con-
sistently associated with increased kinase activity, and mutations in
the ROC and COR domains display reduced GTPase activity [5–9]. How-
ever, thus far no biochemical phenotype has been consistently linked to
mutations in all three of these domains. The only reported cellular phe-
notype that consistently correlateswith penetrantmutations is cytotox-
icity, which is dependent upon kinase activity [10–12].
A number of recent reports have suggested a role for LRRK2 in the
autophagy/lysosomal pathway [13–21]. Data from a range of cell lines
and patient derived cells have revealed alterations in key markers of
autophagy in the presence of mutations in LRRK2, although the precise
point in the pathway that links LRRK2 to this process has not been
identiﬁed [13,14,18–20]. The relationship between LRRK2 and autoph-
agy has been further highlighted by studies in animal models lack-
ing LRRK2 or expressing a mutant form of the protein [15,16,21].
Knockdown studies support a complicated link between LRRK2 and
the induction/regulation of autophagy, in particular the demonstrationved.
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course of mouse development [21]. Data from ﬂy models of LRRK2
dysfunction have suggested that LRRK2 may function in the mTOR
pathway, implicating LRRK2 in a pathway with an important role in
regulating autophagy, although these data have proved controversial
[22,23]. Intriguingly, LRRK2 has also been identiﬁed as a risk factor in
a number of human diseases characterized by a strong pathogenic link
to autophagy (in addition to PD): Crohn's disease, cancer and leprosy
[24–26]. A key research challenge in LRRK2 biology is, therefore, to elu-
cidate the precise role of this protein in autophagy.
To clarify the role of LRRK2 in the regulation of autophagy, this study
takes advantage of recently described inhibitors of LRRK2kinase activity
[27,28] to test whether the kinase activity of endogenous LRRK2 is im-
portant for this pathway at a cellular level, and to delineate the point
at which LRRK2 intervenes in autophagy.
2. Materials and methods
2.1. Inhibitors
The LRRK2-in1 and the CZC-25146 compounds were purchased
from the Department of Biochemistry, University of Dundee, UK. GSK
2578215A was purchased from Tocris Bioscience. Baﬁlomycin A1
(B1793-2UG) and cyclohexamide (01810-1G) were purchased from
Sigma-Aldrich.
2.2. Antibodies
Antibodies used were as follows: rabbit LC3 antibody (NB100-2220,
Novus Biologicals); mouse LC3 antibody (5F10, Nanotools), LRRK2 anti-
bodies (N138/6, NeuroMab and 3514-1, Epitomics); total S6 antibody
(2317, Cell Signalling); phospho Ser235/236S6 antibody (2211S, Cell
Signalling); total P70S6K antibody (sc-8418, Santa Cruz); phospho
Thr389 P70S6K (sc-11759, Santa Cruz); total 4EBP1 (81149, Santa
Cruz); phospho Ser65 4EBP1 (9451S, Cell Signaling); mouse p62 anti-
body (610833, BD Transduction Labs); rabbit p62 antibody (BML-
PW9860-0025, Enzo Life Sciences); mouse WIPI2 antibody (kindly
supplied by Prof. S. Tooze) and mouse β-actin antibody (A1978, Sigma
Aldrich). LRRK2 phosphorylation was assessed using rabbit phospho
Ser935-LRRK2 (5099-1, Epitomics).
2.3. Cell culture, cell treatments
Cell lines were grown in DMEM containing 10% FCS, with the excep-
tion of the mTOR stimulation experiment as described below. Human
neuroglioma H4 cells (ATCC number HTB-148), human neuroblastoma
SHSY5Y (ATCC number CRL-2266) or Human Embryonic Kidney
(HEK) cells (ATCC number CRL-1573) were seeded at a concentration
of 2 × 105 cell/ml in 6 wells plates (2 ml for each well). After 6 hours
from plating, cells were treated with LRRK2 inhibitors LRRK2-in1,
CZC-25146 and GSK 2578215A. The concentrations of inhibitors, as
used during the treatment, are reported in every experiment shown in
the text. All compounds were dissolved in DMSO. For each experiment,
DMSO vehicle controls were added. Cells were incubated overnight
with LRRK2 kinase inhibitors and fresh treatment was replaced the fol-
lowing morning for 2.5 hours before cell lysis.
Cells were then washed once in Dulbecco's phosphate buffered
saline (DPBS) and collected in a lysis buffer containing: 0.5% Triton X-
100, 2 mM ethylene di-ammonium tetra acetic acid (EDTA), 150 mM
NaCl, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS),
protease inhibitors (cOmplete, protease inhibitor cocktail, Roche) and
phosphatase inhibitors (Halt phosphatase inhibitor cocktail, Pierce) in
50 mM TRIS-HCl pH 7.5.
For mTOR pathway experiments, cells were seeded as described
above; mTOR inhibition was achieved by overnight (16 hours) serum
deprivation followed by substitution of the growing medium withEarle’s balanced salts solution for 2 hours. Re-activation of the mTOR
pathway was obtained after starvation by feeding cells with MEM
non-essential amino acid supplement added directly to the Earle's solu-
tion for 30 minutes. Non-starved, starved and amino acid fed cells were
then washed once in DPBS and collected in lysis buffer.
2.4. Primary astrocyte preparation
Primary astrocytes from cortex were isolated from 3 days old rats as
previously described [30]. The tissue was mechanically dissociated
and trypsinized; the obtained cell pellet was plated in high glucose
DMEM containing 10% FBS. After 5 days, cell medium was changed to
20% FBS and then replaced every 5 days. At 15 days microglia were de-
tached by shaking of the ﬂasks at 200 rpm for 2 hours. The remaining
astrocyteswerewashed in PBS, trypsinized and seeded1:2 in newﬂasks
and kept in culture by splitting 1:2when at conﬂuency. Astrocytes were
used for experiments after 21 or 27 days in culture. They were seeded
1 × 106 in 6 wells plates and treated with LRRK2-in1 as described for
H4 cells or plated 2.5 × 105 in 24wells plates containing glass coverslips
coated in 1 mg/ml poly-D-lysine for cell imaging. Puritywas accessed by
immunostainingwith anti-GFAP antibody (1:1000, Abcam)andDyLight
594 Labeled GSL I-isolectin B4 (1:50, Vector Laboratories).
2.5. Immunoblotting
Cell lysates were frozen immediately upon collection; following
thawing, they were clariﬁed by centrifugation at 10,000g for 5 minutes
at 4 °C prior to use. Lysate protein concentrationswere assessed by BCA
assay (BCA Protein Assay Kit, Pierce) and samples containing 10 μg of
proteins were prepared for SDS-PAGE with the addition of NuPAGE
sample buffer (Invitrogen), and denatured for 10 minutes at 70 °C. Elec-
trophoresis was performed using NuPAGE, Novex precasted Bis-Tris 4–
12% gels (Invitrogen), according to the manufacturer's instructions.
After electrophoresis, proteins were transferred to 0.45 μmPVDFmem-
branes (IPVH00010, Immobilon Millipore) for 2 hours. Proteins were
identiﬁed by the appropriate primary and secondary HRP antibodies
and visualized using Enhanced Chemiluminescence (ECL) and X-Ray
ﬁlms (Super RX, medical X-Ray ﬁlm, Fujiﬁlm). Films were acquired as
images in jpg format using an EPSON Perfection 4870 photo scanner
and processed by the ImageJ software (http://rsbweb.nih.gov/ij/) to
quantify area and total intensity of each single band. Statistical analyses
were performed by Prism software (GraphPad) as described in the text.
2.6. Generation of shRNA scramble control/LRRK2 knockdown (KD) stable
H4 cell line
H4 cells were transfected with 2 μg LRRK2 shRNA or scramble
shRNA (V3LHS-644167, Thermo Fisher Scientiﬁc) using Effectene
(Qiagen) transfection reagent according to the manufacturer's instruc-
tions. ShRNA vectors contain a puromycin resistance gene therefore
48 hours post transfection cells were treated with 2 μg/ml puromycin
supplemented DMEM. Media were changed every 2 days (removal of
dead cells) for 2 weeks in order to select for puromycin-resistant cells
containing shRNA.
2.7. Neutral red staining
Cells were treated with DMSO, LRRK2-in1 (1 μMover night) or with
the autophagy inhibitor baﬁlomycin (40 nM, over night); at the end of
the treatment, the cell culture mediumwas supplemented with a solu-
tion of 3-amino-7-dimethylamino-2-methyl-phenazine hydrochloride
(Neutral red, Sigma Aldrich) with a ﬁnal concentration of 80 ng/ml,
for 30 minutes [29]. Cells were washed twice with DPBS and dissolved
in a destaining solution composed of 50% ethanol, 49% deionized
water, 1% glacial acetic acid and the absorbance was recorded by the
use of a multiwell plate reader at the wavelength of 540 nm. For every
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was used to determine protein concentration (BCA assay). Data were
expressed as absorbance at 540 nm normalized to the absorbance
recorded for the BCA assay for every single column within the plate.
The ﬁnal results in the graph were expressed as percentage of Neutral
red staining in comparison with untreated controls.
2.8. Cytotoxicity
Cells were treated with LRRK2 kinase inhibitors as described above;
at the end of the treatment, the cell culture medium was added of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
Sigma Aldrich) to the ﬁnal concentration of 500 μg/ml for 3 hours. Cell
medium was then discarded and the formazan crystals accumulated
within the energetically active cells were dissolved in 100% DMSO and
the absorbance measured using a multiwell plate reader at 570 nm.
The results were reported as percentage of cell viability after treatment
in comparison with DMSO treated, control cells.
2.9. Immunocytochemistry
Cells were seeded onto a sterilized coverslip in 24 wells plates at
the concentration of 2 × 105 cell/ml (0.5 ml each well). Post treat-
ments, cells were washed twice in DPBS and ﬁxed a room temperature
for 15 minutes in a solution of 4% paraformaldehyde in DPBS or in ice
cold methanol at 4 °C (only for 5F10, anti-LC3 antibody). Cells were
washed three times in DPBS, blocked and permeabilized at room
temperature for 30 minutes by using a solution of 15% normal goat
serum (S1000, Vector) and 0.1% Triton X-100 in DPBS. After washing,
cells were incubated overnight at 4 °C with the primary antibody.
Anti-mouse, secondary antibody (Alexa Fluor, emission at 568 nm) or
anti-rabbit, secondary antibody (Alexa Fluor, emission at 488 nm)
were used to reveal the primary antibody staining and nuclei were
labeled with Hoechst 33342. Coverslips were sealed with Fluoromount
G mounting medium (Southern Biotech). Images were acquired with
a Leica CTR 6000 ﬂuorescence microscope, and processed by the LAS
AF Lite software or with a Zeiss LSM 710 confocal microscope and
processed by the Zen 2009 software.
Cells containing WIPI2 or p62 puncta were manually counted by a
blinded operator using the acquired images and the cell counter plugin
tool from ImageJ software. Graphs and statistical analyses were per-
formed using Prism software.
For p62 puncta, images were acquired at 40×magniﬁcation (DMSO
treated cells: 3 different ﬁelds in 6 independent slides; LRRK2-in1 treat-
ed cells 1 μM: 3 different ﬁelds in 6 independent slides; LRRK2-in1
treated cells 5 μM: 3 different ﬁelds in 2 independent slides; cells
under starvation: 3 different ﬁelds in 4 independent slides; each ﬁeld
contained an average of 130 cells. Wild-type, scrambled and LRRK2
KD H4 cells: 3 different ﬁeld in 2 independent slides; an average of
305 cells was analyzed for each condition).
For WIPI2 puncta, images were acquired at 63× magniﬁcation
(DMSO treated cells: 9 different slides with an average number of
113.6 total cells each; LRRK2-in1 treated cells 1 μM: 9 different slides
with an average number of 137.8 cells each; LRRK2-in1 treated cells
5 μM: 2 different slides with an average number of 88.5 total cells
each; cells under starvation: 5 different slides with an average number
of 146.2 cells each).
Colocalization was determined by the use of the Volocity soft-
ware. colocalization was calculated following the instructions re-
ported in the Perkin-Elmer website: http://www.perkinelmer.co.uk/
pages/020/cellularimaging/training/theorycolocalizationanalysis.xhtml
http://www.perkinelmer.co.uk/pages/020/cellularimaging/training/
performingcolocalizationanalysisvolocity.xhtml.
After threshold correction for the background, Pearson's correlation co-
efﬁcient (perfect correlation = 1; no correlation = 0; perfect invertedcorrelation = −1) is indicated as PCC; Mander's colocalization coefﬁ-
cients (i.e. showing the overlapping between the channels) are indicated
as Mgreen and Mred.
2.10. Z-stack movies
Z-stacks were acquired using a Zeiss LSM 710 confocal microscope
using the Zen 2009 imaging software (Zeiss). The ﬁrst frame was ﬁxed
by the operator as theﬁrst zoom level inwhich the green signal was vis-
ible. The last frame was then selected by unzooming until the green
ﬂuorescence disappeared. The thickness of the slices within the total
volume between the ﬁrst and the last frame was selected according to
the software suggestions. 3D movies generated by the Zen software
based on the acquired z-stacks were selected for speed, rotation angle,
zoom and number of frames and were exported as avi ﬁles. Avi movies
and correspondent freeze-frameswere composed in a storyboard by the
use of the Windows Live Movie Maker program and ﬁnally saved as
wmv ﬁles.
3. Results
Recent data indicate LRRK2 is expressed in glial cells and that it has a
key, functional role in orchestrating the inﬂammatory response of this
cell population [31,32]. A number of reports have highlighted dynamic
expression of LRRK2 in a range of immune cells; thus leading to the hy-
pothesis that LRRK2 may drive a function related with the innate im-
mune response [33,34]. Based upon these investigations, the human
neuroglioma cell line H4 was selected as a model system to investigate
endogenous LRRK2 function in non-neuronal populations. Using con-
version of LC3-I to LC3-II by conjugation to phosphatidylethanolamine
as a marker for alterations in autophagy [35], the cellular response of
H4 cells in the presence of a speciﬁc inhibitor of LRRK2 kinase function,
LRRK2-in1 [28], was examined. Overnight treatment of H4 cells with
LRRK2-in1 resulted in a signiﬁcant increase in the detectable levels of
LC3-II compared to vehicle (DMSO) treated cells (Fig. 1A). The increase
in LC3-II accumulation followed a dose response trend (Fig. 1B) andwas
not associated with cytotoxicity (as measured by MTT assay) in the
concentration range of 1–5 μM (Fig. 1C). A small toxic effect was
recorded with 10 μM inhibitor; for this reason the maximum concen-
tration of LRRK2-in1 used for all subsequent experiments was 5 μM. A
similar response to LRRK2 kinase inhibition was observed in SHSY-5Y
and HEK293T cells (Supplemental Fig. S1).
To determine if the increase in LC3-II was due to inhibition of LRRK2
kinase activity or to an off target impact of LRRK2-in1, a dose response
with a structurally distinct inhibitor of LRRK2 kinase activity, CZC-
25146 (Supplemental Fig. S2A), was carried out [27]. This resulted in a
similar increase in LC3-II, albeit at higher concentrations than LRRK2-
in1 (Supplemental Fig. S2B). A similar response was seen with an addi-
tional LRRK2 kinase inhibitor, GSK 2578215A (Supplemental Fig. S2C)
[36]. To assess whether treatment of H4 cells with LRRK2-in1 results
in inhibition of LRRK2 kinase activity ex vivo, analysis of phosphoryla-
tion of LRRK2 at residue S935, which can be correlated with LRRK2
kinase activity despite not being a direct autophosphorylation event
[28], was carried out. This revealed the expected decrease in phosphor-
ylation in the presence of LRRK2-in1 (Supplemental Fig. S2D).
An H4 LRRK2 stable knockdown line (generated using a shRNA con-
struct, resulting in a ≈ 60% decrease in LRRK2 expression) was then
used to test whether the increase in LC3-II upon LRRK2-in1 treatment
was a LRRK2 dependent phenomenon, and not an off target effect of
the inhibitor. Upon treatment with LRRK2-in1, the LRRK2 knockdown
cells displayed a signiﬁcantly reduced response compared to wild type
H4 cells and to scrambled shRNA cells (Fig. 1D), with a concomitant re-
duction in the response of cells over a range of doses (Supplemental
Fig. S2E).
To investigatewhether the alteration in LC3-II levels upon inhibition
of LRRK2 was due to an induction of autophagy (that is, an increase in
Fig. 1. Inhibition of LRRK2 alters the autophagy/lysosomal pathway in H4 neuroglioma cells. A) LC3-II levels increase upon LRRK2-in1 inhibitor treatment (1 μM, overnight treatment;
quantiﬁcation from 3 independent replicates, the plot shows mean and SD, * indicates signiﬁcance (p b 0.05)). B) Dose dependent increase in LC3-II upon overnight treatment with
LRRK2-in1. C) MTT assay showing no alteration of cell viability upon over night treatment with LRRK2-in1 from 1 to 5 μM. A small toxic effect appeared with the higher dose (10 μM).
The plot shows mean and SD, * indicates signiﬁcance (p b 0.05). D) LRRK2 knockdown cells display reduced response to LRRK2-in1. LRRK2 protein levels are decreased in shRNA stable
line compared to wild type cells (right panel), and knockdown of LRRK2 reduces response to 1 μM LRRK2-in1 treatment compared to wild type or scrambled shRNA cells (left panel).
E)Western blot analysis of H4 cells treated with DMSO and LRRK2-in1 (5 μM, 2.5 hours treatment) in the presence and absence of 40 nM baﬁlomycin added at the same time as the in-
hibitor. Quantiﬁcation of three replicates is shown in the right handpanel, the plot showsmean and SD, * indicates signiﬁcance (p b 0.05). F) LRRK2-in1 increases LC3-II levels independent
of mTORC1 activity. P70S6K and phoshoThr389-P70S6K; S6 and phosphoSer235/236-S6 levels are shown in control, starvation and amino-acid stimulated conditions. LRRK2-in1 (1 μM
over night) treatment doesnot alter phosphorylation of P70S6K and S6 in conditions that show increased levels of LC3-II. G)Neutral red staining. Theplot showsmean and SEM. * indicates
signiﬁcance (p b 0.05).
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response of H4 cells to LRRK2-in1 was assessed in the presence of
baﬁlomycin, an inhibitor of lysosomal acidiﬁcation [26] (Fig. 1E). As
expected, LC3-II levels were increased in both DMSO and LRRK2-in1
treated cells in the presence of baﬁlomycin, with the LRRK2-in1 plus
baﬁlomycin treated cells displaying a signiﬁcantly higher level of LC3-
II compared to the LRRK2-in1 only and the DMSO plus baﬁlomycin
treated cells. This suggests that the increase in LC3-II levels in LRRK2-
in1 treated cells is due to an increase in production rather than the de-
creased recycling of the lipid conjugated form of LC3. To examine if
LRRK2 kinase inhibition impacts on autophagic recycling using an alter-
native approach, the presence of low pH vesicles was assessed using
neutral red, a dye that is speciﬁcally retained by acidic vesicles [29]. As
expected, baﬁlomycin markedly decreased the staining with this dye
(Fig. 1F). In contrast, neutral red staining in LRRK2-in1 treated cellswas statistically indistinguishable from DMSO treated cells. This sup-
ports a role for LRRK2 kinase activity in autophagocytosis independent
of vesicle acidiﬁcation.
Previous studies have suggested that LRRK2 may operate in the
mTOR pathway regulating protein synthesis through the phosphoryla-
tion of 4EBP1 [25], although whether this is a physiological interaction
is unclear [23,37]. To determine if the alteration in LC3-II levels upon
LRRK2 inhibition is due to upstream alterations in the mTOR pathway
the phosphorylation of p70S6K, S6 and 4EBP1 (downstream transla-
tional inhibition targets of mTORC1) was examined in the presence of
LRRK2-in1. To modulate the mTOR pathway, cells were starved of
amino acids (inhibiting mTORC1), and then re-exposed to amino acids
to re-active the pathway. No reduction in the level of phosphorylation
of target proteins was observed in the presence of LRRK2 kinase inhibi-
tors (Fig. 1F, Supplemental Fig. S3), suggesting that, at the endogenous
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mTORC1 signaling to induce autophagy.
To examine autophagic clearance, p62 levels were examined in the
presence and absence of LRRK2-in1. This revealed a surprising increase
in total levels of p62 upon treatment with LRRK2-in1 (Fig. 2A). During
starvation (stimulating autophagy through inhibition of mTORC1) an
expected decrease in the total level of p62 was shown for both DMSO
and LRRK2-in1 treated cells, however the level of p62 still remained
higher in starved cells treated with the LRRK2 kinase inhibitor in com-
parison with starved controls (Fig. 2B). This increase in total p62 levels
was not visible upon a shorter treatment with LRRK2-in1 (data not
shown), it appeared only after an overnight cell exposure to the com-
pound. Based upon a previous report by Gomez-Suaga and co-workers
[17], who observed a translation-dependent increase in p62 levels
upon manipulation of LRRK2, LRRK2-in1 treatment was carried out in
the presence of cyclohexamide. This blocked the previously observed
increase in p62, suggesting this phenomenon is driven by increased syn-
thesis of p62 rather than decreased turnover (Fig. 2C).More experimentsFig. 2. The impact of LRRK2-in1 on p62 levels A) p62 levels increase upon overnight treatmen
B)Analysis of p62 levels under control and starvation conditions. Reduced levels of total p62 und
the treatmentwith LRRK2-in1 (1 μM, over night) is able to impact onto total p62 levels even un
treated with DMSO and LRRK2-in1 (5 μM, overnight treatment) in the presence and absence o
* indicates signiﬁcance (p b 0.05).are required to verify if this is a direct effect due to LRRK2 kinase inhibi-
tion or whether it is an off target effect of the LRRK2-in1 compound.
It is noteworthy that, in parallel to the increased levels of LC3-II, an
increase in LC3-I levels is also observed (for example Supplemental
Fig. S2B). In H4 cells this occurs only after 24 hours of LRRK2 kinase
inhibition, and is not observed after 2.5 hours of inhibition (Supplemen-
tal Fig. S4), suggesting that this is a consequence of the increased au-
tophagic ﬂux rather than driving this phenomenon. In contrast to p62,
inhibition of translation with cyclohexamide, while decreasing LC3
levels globally, does not alter the increase in LC3-I levels in response
to LRRK2 kinase inhibition (Supplemental Fig. S4). This suggests that
this phenomenon is not due to an increase in the translation of LC3, in-
stead being a result of the increase in autophagic ﬂux upon inhibition of
LRRK2 kinase activity.
To conﬁrm the inhibition of LRRK2 kinase activity results in a change
in the autophagy ﬂux similar to the effect of starvation, the formation
of autophagosomes was assessed by immunocytochemistry. Treat-
ment with LRRK2-in1 at two different concentrations resulted in thet with LRRK2-in1 (1 μM). The plot shows mean and SD, * indicates signiﬁcance (p b 0.05)
er starvation conditions for bothDMSOand LRRK2-in1 treated cells are detected, however
der starvation. C) Impact of LRRK2-in1 upon p62 in the presence of cyclohexamide. H4 cells
f 50 μg/ml cyclohexamide. The plot showmean and SD, statistical analysis was by ANOVA.
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expected and observed in cells in which autophagy has been stimulated
by starvation [38]. The percentage of cells containing p62 clusters or
WIPI2 positive puncta was signiﬁcantly increased upon inhibitor treat-
ment (Fig. 3) but not in cells in which LRRK2 has been constitutively
knocked down (Fig. 4) thus conﬁrming the alteration of autophagy
following inhibitor treatment is mediated by endogenous LRRK2 and
is not a generic off-target effect. Both LRRK2-in1 and starved cells also
displayed LC3 positive puncta further supporting a role for LRRK2 kinaseFig. 3. Immunocytochemical analysis of control, LRRK2-in1 (1 and 5 μM) treated and starved H
10 μm. Mean and SD are displayed for both plots, statistical analysis was by ANOVA. *indicatesactivity as an important regulator of autophagy and suggesting that the
process initiated by inhibition of LRRK2 kinase activity is biologically
equivalent to autophagy induced by inhibition ofmTORC1 by starvation.
To further examine the nature of the puncta produced upon in-
hibition of LRRK2 kinase activity, the distribution and colocalization of
WIPI2, LC3 and p62, reﬂecting autophagosomes at different stages of
maturation, were examined. Starved samples were indistinguishable
from H4 cells after treatment with LRRK2-in1, demonstrating that,
from a structural point of view, both treatments were able to generate4 cells. A) p62 (green), B) WIPI2 (red) and nuclear staining in blue. Scale bar represents
signiﬁcance (p b 0.05).
Fig. 4. Immunocytochemical analysis of control, scrambled and LRRK2 knock down H4
cells after 5 μM LRRK2-in1 over night treatment. p62 (green) and nuclear staining in
blue. Mean and SD are displayed in the plot, statistical analysis was by ANOVA. *indicates
signiﬁcance (p b 0.05).
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staining but no proper colocalization was detected (Fig. 5 and Supple-
mental Movie 1). Partial colocalization between p62 and LC3 was ob-
served (Fig. 6 and Supplemental Movie 2), as has previously been
reported for endogenous levels of LC3 and p62 [39]. Importantly, therewas a similar distribution ofWIPI2, LC3 and p62 colocalization observed
in LRRK2-in1 treated cells and in starved cells, again suggesting that the
puncta induced by LRRK2 kinase inhibition are equivalent to those in-
duced by starvation.
Finally, to assess how the data suggesting that inhibition of LRRK2
induces autophagy in model cell lines relates to primary cells, primary
astrocytes isolated from rat brain were treated with LRRK2-in1. Astro-
cytes were selected as a cell type to carry out these experiments based
upon previous data highlighting LRRK2 expression in these cells [30],
and to march as closely as possible to the H4 cells used as the main
cell model in this study (H4 cells are classiﬁed as a neuroglioma line,
but are likely to have been derived from an astrocytoma [40,41]). Im-
munocytochemical analysis of an astrocyte speciﬁc marker (glial
ﬁbrillary acidic protein, GFAP) demonstrates successful enrichment of
these cells in the ex vivo population, with minimal contamination with
microglial cells as assessed by staining with Lectins (Fig. 7A). As previ-
ously reported [30], full length LRRK2 is expressed at an endogenous
level in astrocytes, at a level comparable to that seen in H4 cells
(Fig. 7B). Treatment of astrocytes with 10 μM LRRK2-in1 was not asso-
ciated with detectable toxicity (data not shown), and resulted in an in-
crease in LC3-II as previously observed for H4 cells (Figs. 7C and D)
consistent with an induction of autophagy.
4. Discussion
Since 2004, when LRRK2 was ﬁrst implicated in the pathogenesis of
PD, a number of cellular processes have been linked to the function of
this protein, including a putative role in the regulation of autophagy.
In this study, the effect of pharmacological inhibition of LRRK2 kinase
activity upon autophagy has been assessed. The results reported above
document an increase in LC3-II formation and in LC3, WIPI2 and p62
positive puncta in response to treatment with an inhibitor of LRRK2
kinase activity, LRRK2-in1. Carrying out these investigations in the
presence of baﬁlomycin, thereby examining the impact of LRRK2 kinase
inhibition upon autophagic ﬂux, suggests that the increase in LC3-II and
puncta is due to an induction of autophagy— placing LRRK2upstreamof
the initiation of autophagy.
A key advantage in taking a pharmacological approach is that it al-
lows examination of endogenous LRRK2's function, removing the need
to overexpress LRRK2. Due to its complicated domain structure and
multiple enzymatic activities, the overexpression of LRRK2 results in
the upregulation of its kinase activity, GTPase activity and its putative
role as a scaffolding protein. Although it is possible that these activities
are complementary, too little is known about the biology of LRRK2 to be
conﬁdent that these different domains do not have divergent functions
within the cell. Therefore, by using speciﬁc inhibitors against the kinase
activity of LRRK2 at an endogenous level, a more reductionist approach
can be taken — taking one aspect of LRRK2’s biology and examining it
in isolation, in so much as this is possible. Using this approach, the
data from this study conﬁrm and support a role for LRRK2 kinase activ-
ity in the regulation of the induction of autophagy in H4 human
neuroglioma cells. As outlined in Results section, these cells were cho-
sen as a model system based upon the increasing evidence linking
LRRK2 to a role in the immune system. Although the majority of the
data in this study are derived from H4 cells, it should be noted that a
similar effect on autophagy following the inhibition of LRRK2 kinase ac-
tivity was observed in SHSY5Y cells (a neuroblastoma cell line) and, to a
lesser extent, in human embryonic kidney cells, suggesting this is a con-
sistent feature of LRRK2 kinase inhibition across a number of different
cell lines (Supplemental Fig. S1). Importantly, primary astrocytes isolat-
ed from rat brain respond in a similar fashion to the H4 cells used in this
study, suggesting that the results from the immortalized cell model
used in this study can be at least partially extrapolated to primary
cells. With regard to the nature of the vesicles created following inhibi-
tion of LRRK2 kinase activity, data from immunoblot and immunocyto-
chemical analysis following LRRK2 kinase inhibition, carried out in
Fig. 5. Immunocytochemical analysis for WIPI2 (red) and p62 (green) colocalization. A) starved H4 cells PCC = 0.240, Mgreen = 0.952 Mred = 0.952. B) 5 μM, LRRK2-in1 overnight
treated cells PCC = 0.231, Mgreen = 0.824 Mred = 0.852. Three different spots were selected from the zoomed images and 5 μm intensity proﬁles were drawn as indicated by the
white lines.
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protocol, suggest that targeting the kinase activity of LRRK2 induces
an autophagic response analogous to that observed upon inhibition of
mTORC1 by starvation.
An important piece of evidence supporting this conclusion is the
equivalence in the pattern of puncta produced by H4 cells in response
to exposure to LRRK2-in1 and to growth under starvation condition
(inhibitingmTORC1). Under both conditions, amixed population of ves-
icles labeled with WIPI2, LC3 and p62 is observed. As has previously
been reported [38,39], this is representative of autophagosomes at dif-
ferent stages in their maturation, with a proportion in each case labeled
with different combinations of WIPI2, LC3 and p62. The fact that a
similar pattern of colocalization is observed under both experimental
conditions (and absent in the control cell population) supports the
proposition that both LRRK2 kinase inhibition and starvation produce
a similar autophagic response.
Despite the similarities in the autophagic response to the two experi-
mental conditions described above, an important mechanistic ﬁnding
from this study is that the induction of autophagy following LRRK2 kinase
inhibition is independent of an alteration in translational downstream
targets of mTORC1, S6 and 4EBP1. There are two possible explanations
for this observation. First, inhibition of LRRK2 could be inducing autopha-
gy through a speciﬁc regulation ofmTORC1 activity that is independent of
its role as a translational regulator. Second, LRRK2 could be regulating the
induction of autophagy in an mTORC1 independent manner. Further in-
vestigations are required to distinguish between these equally intriguingpossibilities, in particular directly inhibiting/knocking down mTORC1 to
test whether the induction of autophagy in response to LRRK2 kinase in-
hibition is an mTORC1 dependent phenotype.
One difference between the autophagic response observed in
starved cells versus that seen in LRRK2-in1 treated cells is the surprising
increase in p62 levels as measured by immunoblot upon inhibition of
LRRK2 kinase activity. As noted in Results section, it would be expected
that the induction of autophagywould result in a decrease of in p62 levels
due to its status as a degradation target for autophagy. A previous study
[17] noted that manipulation of LRRK2 leads to an increase in p62 levels
due to an increase in translation, and this has been replicated under
the experimental conditions used in the experiments described above —
inhibition of translation using the inhibitor cyclohexamide blocked the in-
crease in p62 observed upon treatment with LRRK2-in1.While this result
explains the paradoxical increase in p62 levels, it does not reveal the
mechanism whereby LRRK2 inhibition results in a translational increase
in p62, an observation that merits a more detailed exploration.
There are a number of caveats to the interpretation of the data in
this study. First and foremost is the possibility that the cellular pheno-
types observed resulted from off target effects of the LRRK2 kinase in-
hibitors used. To minimize the likelihood of this, two approaches have
been used: ﬁrst, three structurally dissimilar (including two structurally
distinct) inhibitors of LRRK2 kinase function have been used, with sim-
ilar cellular consequences albeit at differing concentrations. Given that
LRRK2-in1, CZC-25146 and GSK 2578215A exhibit different spectrums
of off target effects, the coincidence of the autophagic phenotype
Fig. 6. Immunocytochemical analysis for LC3 (red) and p62 (green) colocalization. A) Starved H4 cells PCC = 0.399, Mgreen = 0.830Mred = 0.949. B) 5 μM, LRRK2-in1 overnight treat-
ed cells PCC = 0.403, Mgreen = 0.936 Mred = 0.978. C–D) images from starved or 5 μM, LRRK2-in1 overnight treated H4 cells have been crossed by 5 lines and the relative intensity
proﬁles have been drawn to better show the partial colocalization of LC3 and p62.
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this is due to an impact other than a decrease in LRRK2 kinase activity.
Secondly, the demonstration that LRRK2 knock down cells display a re-
duced response to treatment with LRRK2-in1 highlights the LRRK2 de-
pendence of the autophagic response to LRRK2-in1 treatment. Taken
together, these two sets of data strongly suggest that the induction of
autophagy observed upon inhibition of LRRK2 kinase activity is a specif-
ic phenotype rather than an off target effect.
The experiments performed with LRRK2 knockdown H4 cells also
raise a number of questions as to the nature of the interplay between
LRRK2 and autophagy. Foremost amongst these is why, since treatment
with LRRK2-in1 is a pharmacological method of reducing the activity of
this protein, does the knockdown of LRRK2 not result in a similar in-
duction of autophagy? A number of observations in the existing litera-
ture suggest why this may be the case. First, LRRK2 knockout (that is,
removing LRRK2 completely from the developmental process) has a
complicated, biphasic impact on steady state levels of autophagy inmice [21]. This suggests there may be a number of compensatory path-
ways that are engaged following the removal of LRRK2. Indeed, given
the importance of autophagy to cell survival it is to be expected that
multiple pathways will be involved in its regulation, resulting in a de-
gree of redundancy in the system [42]. With reference to this, it should
be noted that the H4 LRRK2 knockdown cells used in these experiments
were selected over a period of several weeks to generate a pooled stable
line, and so the removal of LRRK2 activity in these cells is qualitatively
different to that following acute treatment of cells with LRRK2-in1. In-
deed, a previous study reported that when cells are subjected to acute
knockdown of LRRK2 by siRNA treatment the result is an increase in
LC3-II levels, consistent with the induction of autophagy upon acute
LRRK2 kinase inhibition observed in the current experiments [14].
Amore complicated caveat applies to the interpretation of LRRK2 ki-
nase activity inhibition in the context of holistic LRRK2 protein function.
The aim of this study, as outlined above, was to assess the role of LRRK2
in the regulation of autophagy in a reductionist model, targeting only
Fig. 7. Inhibition of LRRK2 kinase activity induces autophagy in rat primary astrocytes. A) Immunocytochemical analysis of astrocytes isolated from rat brain, showing staining for DAPI,
GFAP (expressed by astrocytes) and Lectin (staining for microglia). B) Astrocytes express LRRK2 at a level equivalent to H4 neuroglioma cells. C) Treatment of astrocytes with LRRK2-in1
results in an increase in LC3-II as analysed by immunoblot. D) Quantiﬁcation of increase in LC3-II. The plot shows mean and SEM. * indicates signiﬁcance (p b 0.05).
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er, suggest that the kinase and GTPase activities of LRRK2 are intimately
linked, although the exact nature of this relationship remains to be com-
pletely delineated [43–45]. This being the case, it is important to note
that with current tools it is impossible to exclude a reciprocal impact
on GTPase activity following the inhibition of LRRK2 kinase activity. A
further complicating factor is the possibility that the two enzymatic ac-
tivities may have completely separate, or even antagonistic, cellular
roles [46], and this eventuality should be considered when evaluating
the impact of LRRK2 kinase inhibition or gene knock down. Clarifying
the roles of the different enzymatic activities of LRRK2 in its function
will depend upon the development of tools to target the GTPase activity
of LRRK2 [47], and is a major challenge for the ﬁeld.
In summary, the data in this study provide a key insight into the
mechanism whereby LRRK2 regulates autophagy, underscoring a role
for the kinase activity of this protein in the control of the induction of
autophagy and placing LRRK2 upstream of the initiation of this process.
The experiments reported here focus on the physiological role of en-
dogenous LRRK2, however the driving force behind LRRK2 research is
the role for this protein in a number of human diseases. Although the
links between kinase activity and LRRK2 PD are amatter of somediscus-
sion [48], it is clear that kinase activity does play an important, and per-
haps central, role in the disease process. Given current efforts to develop
LRRK2 kinase inhibitors [36], and the potential therapeutic use of these
inhibitors in Parkinson's disease, it is clearly a priority to characterize
the cellular impact of LRRK2 kinase inhibition, and a more detailed dis-
section of the mode of action of these inhibitors with regard to autoph-
agy is an urgent need. As such, the ﬁnding that inhibiting LRRK2 kinase
activity stimulates autophagy clearly has implications for the etiology of
LRRK2 PD. It is also of interest that all of the diseases LRRK2 has been as-
sociated with have also had autophagy implicated in their pathogenesis
[49–53]. Exploring the links between LRRK2, autophagy and human dis-
ease are, therefore, important areas for future research into this protein.
Supplementary data to this article can be found online at http://dx.
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